Atai Life Sciences N.V. [ATAI] Investment Appeal on the Rise

Atai Life Sciences N.V.’s recent filing unveils that its 10% Owner Apeiron Investment Group Ltd. acquired Company’s shares for reported $1.6 million on Mar 29. In the deal valued at $1.32 per share,1,214,297 shares were bought. As a result of this transaction, Apeiron Investment Group Ltd. now holds 32,086,697 shares worth roughly $ 49.41 million.

Then, Brand Florian bought 70,000 shares, generating $103,558 in total proceeds. Upon buying the shares at $1.48, the insider now owns 70,000 shares.

Loop Capital initiated its Atai Life Sciences N.V. [ATAI] rating to a Buy in a research note published on Friday, November 01, 2022; the price target was $18. PT values the company’s stock at a premium of 91.44 to its Friday closing price.

Price Performance Review of ATAI

On Friday, Atai Life Sciences N.V. [NASDAQ:ATAI] saw its stock jump 0.65% to $1.54. On the same session, the stock had its day’s lowest price of $1.51, but rose to a high of $1.57. Atai Life Sciences N.V. shares have fallen nearly -42.11% since the year began. Nevertheless, the stocks have fallen -65.78% over the past one year. While a 52-week high of $4.52 was reached on 01/04/23, a 52-week low of $1.14 was recorded on 03/15/23. SMA at 50 days reached $1.8220, while 200 days put it at $1.9877. A total of 0.6 million shares were traded, compared to the trading of 0.71 million shares in the previous session.

Levels Of Support And Resistance For ATAI Stock

The 24-hour chart illustrates a support level at 1.5100, which if violated will result in even more drops to 1.4800. On the upside, there is a resistance level at 1.5700. A further resistance level may holdings at 1.6000. The Relative Strength Index (RSI) on the 14-day chart is 34.95, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0462, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.33%. Stochastics %K at 9.90% indicates the stock is a buying.

How much short interest is there in Atai Life Sciences N.V.?

A steep rise in short interest was recorded in Atai Life Sciences N.V. stocks on Aug 14, 2023, growing by 50000.0 shares to a total of 4.13 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 4.08 million shares. There was a rise of 1.21%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 3.25% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.35.

Atai Life Sciences N.V. [ATAI] – Who Are The Largest Shareholders?

In filings from Morgan Stanley Investment Managem, it is revealed that the company now owns 1,612,137 shares, or roughly 0.97% of the outstanding ATAI shares. In other words, the investor’s shares have fallen by -28,477 from its previous 13-F filing of 1640614.0. Additionally, BlackRock Fund Advisors decreased -12.07% of its stake after which the total value it holdings stand at $2,804,306, while Millennium Management LLC added 51.01% of its stake to hold $2.32 million in the firm. Over the last quarter, Cerity Partners LLC sold -419,200 shares of Atai Life Sciences N.V., while SSgA Funds Management, Inc. sold 403,661 shares. At present, BlackRock Advisors is holding 818,262 shares valued at $1.71 million. Brown University Investment Offic owned 718,500 shares of the company at the time of its most recent 13F filing, worth $1.5 million.

According to FactSet, Atai Life Sciences N.V.’s share price will average $11.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 618.95 percent from its previous closing price of $1.53. Analysts expect Atai Life Sciences N.V. stock to reach the higher price of $21.00, while the lowest price estimate is $5.10. However, 11 analysts have rated ATAI stock as a Buy in their predictions for 2023.